HOW CAN WE HELP YOU? Call 1-800-TRY-CHOP
AAML1921; Bosutinib for Chronic Myeloid Leukemia
This study is now recruiting.
This study involves taking a study drug called bosutinib. The overall goals of this study are to find the best dose of bosutinib that we can give safely, and to find out what effects, good and/or bad, bosutinib has on children and adolescents with Chronic Myeloid Leukemia (CML).
Who Do I Contact?
If you are interested in participating in the study or want to learn more please contact our study team at RODRIGUECS [at] chop.edu or 267-426-9293.
Eligibility & Criteria
IRB #:
20-017915
Official Title:
AAML1921, A Phase I/II study of Bosutinib in pediatric patients with newly diagnosed chronic phase or resistant/intolerant Ph+ Chronic Myeloid Leukemia, study ITCC-054/COG AAML1921
Study Phase:
Phase I
Phase II
Eligible Age Range:
1 - 17 Years
Gender:
All
Study Categories:
Visit Criteria
Participation will last for up to 10 years. Subjects will receive Bosutinib once daily. Study visits include the following assessments: blood draws, bone marrow aspirate (if procedure is performed as part of regular clinical care), collection of extra blood and tissue for future research, and the completion of diaries and questionnaires.
